Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MHRA
Biotech
Traws defers midphase flu study after negative regulatory review
Regulators issued a “negative review” of Traws' planned flu challenge study, forcing the biotech to defer a phase 2a tied to $20 million in funding.
Nick Paul Taylor
Jun 15, 2026 9:19am
Fierce Pharma
UK reveals life sciences plan in sweeping strategy update
Jun 23, 2025 3:55pm
FDA elevates recall as Zimmer Biomet phases out hip implant
Sep 17, 2024 2:40pm
FDA joins international push for transparency in AI development
Jun 14, 2024 12:00pm
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
ViroCell gets UK nod to produce viral vectors at London facility
Nov 2, 2023 9:50am
